The effect of dexmedetomidine on anxiety levels in electroconvulsive therapy

Studying the effect of premedication with dexmedetomidine on anxiety levels in patients undergoing electroconvulsive therapy

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20211011052726N7

Enrollment

120

Registered

2026-04-18

Start date

2026-05-22

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety induced by ECT. Anxiety disorder due to known physiological condition

Interventions

Intervention 1: Control group: Placebo group (receiving normal saline). Intervention 2: Intervention group: Dexmedetomidine 0.25 µg/kg. Intervention 3: Intervention group: Dexmedetomidine 0.5 µg/kg. I

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: ASA status index = 2 No history of allergy to study drugs. Written informed consent from the patient or legal guardian

Exclusion criteria

Exclusion criteria: Presence of severe underlying cardiac diseases (e.g. arrhythmias, 2nd and 3rd degree AV block) History of refractory or prolonged seizures Use of benzodiazepine, anticonvulsant or antianxiety drugs in the past 24 hours Severe hepatic or renal disordersPregnancy or lactation Non-cooperation or withdrawal at any stage of the study

Design outcomes

Primary

Measure	Time frame
Anxiety Level (by STAI questionnaire). Timepoint: Before the ECT. Method of measurement: STAI Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNafiseh Faghani Makrani

Mazandaran University of Medical Sciences

dr.nfaghani@gmail.com+98 11 3336 1700

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026